American Journal of Kidney Diseases
Volume 53, Issue 5 , Pages 770-778 , May 2009

Angiopoietin 2 and Cardiovascular Disease in Dialysis and Kidney Transplantation

  • Sascha David, MD

      Affiliations

    • Division of Nephrology and Hypertension, Medical School Hannover, Hannover, Germany
    • Corresponding Author InformationAddress correspondence to Sascha David, MD, Department of Medicine, Division of Nephrology, Medical School Hannover, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany
    • ,
  • Philipp Kümpers, MD

      Affiliations

    • Division of Nephrology and Hypertension, Medical School Hannover, Hannover, Germany
    • ,
  • Julian Hellpap

      Affiliations

    • Division of Nephrology and Hypertension, Medical School Hannover, Hannover, Germany
    • ,
  • Rüdiger Horn

      Affiliations

    • Division of Gastroenterology, Hepatology, and Endocrinology, Medical School Hannover, Hannover, Germany
    • ,
  • Holger Leitolf, MD

      Affiliations

    • Division of Gastroenterology, Hepatology, and Endocrinology, Medical School Hannover, Hannover, Germany
    • ,
  • Hermann Haller, MD

      Affiliations

    • Division of Nephrology and Hypertension, Medical School Hannover, Hannover, Germany
    • ,
  • Jan T. Kielstein, MD

      Affiliations

    • Division of Nephrology and Hypertension, Medical School Hannover, Hannover, Germany

Received 22 July 2008 ,Accepted 13 November 2008.

References 

  1. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038–2047
  2. Sarnak MJ. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis. 2003;41:11–17
  3. Kilpatrick RD, McAllister CJ, Kovesdy CP, et al. Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol. 2007;18:293–303
  4. Kielstein JT, Boger RH, Bode-Boger SM, et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: Relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol. 1999;10:594–600
  5. Kielstein JT, Zoccali C. Asymmetric dimethylarginine: A cardiovascular risk factor and a uremic toxin coming of age?. Am J Kidney Dis. 2005;46:186–202
  6. Caglar K, Yilmaz MI, Saglam M, et al. Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol. 2008;3:61–68
  7. Zoccali C, Bode-Boger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study. Lancet. 2001;358:2113–2117
  8. Roberts MA, Hare DL, Ratnaike S, Ierino FL. Cardiovascular biomarkers in CKD: Pathophysiology and implications for clinical management of cardiac disease. Am J Kidney Dis. 2006;48:341–360
  9. Fam NP, Verma S, Kutryk M, Stewart DJ. Clinician guide to angiogenesis. Circulation. 2003;108:2613–2618
  10. Brindle NP, Saharinen P, Alitalo K. Signaling and functions of angiopoietin-1 in vascular protection. Circ Res. 2006;98:1014–1023
  11. Fiedler U, Augustin HG. Angiopoietins: A link between angiogenesis and inflammation. Trends Immunol. 2006;27:552–558
  12. Kim I, Kim HG, So JN, et al. Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Circ Res. 2000;86:24–29
  13. Findley CM, Cudmore MJ, Ahmed A, Kontos CD. VEGF induces Tie2 shedding via a phosphoinositide 3-kinase/Akt dependent pathway to modulate Tie2 signaling. Arterioscler Thromb Vasc Biol. 2007;27:2619–2626
  14. Thurston G, Rudge JS, Ioffe E, et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med. 2000;6:460–463
  15. Witzenbichler B, Westermann D, Knueppel S, Schultheiss HP, Tschope C. Protective role of angiopoietin-1 in endotoxic shock. Circulation. 2005;111:97–105
  16. Lim HS, Lip GY, Blann AD. Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: Relationship to VEGF, glycaemic control, endothelial damage/dysfunction and atherosclerosis. Atherosclerosis. 2005;180:113–118
  17. Nykanen AI, Krebs R, Saaristo A, et al. Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. Circulation. 2003;107:1308–1314
  18. Lee KW, Lip GY, Blann AD. Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor Tie-2, and vascular endothelial growth factor levels in acute coronary syndromes. Circulation. 2004;110:2355–2360
  19. Parikh SM, Mammoto T, Schultz A, et al. Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med. 2006;3:e46
  20. Yuan HT, Tipping PG, Li XZ, Long DA, Woolf AS. Angiopoietin correlates with glomerular capillary loss in anti-glomerular basement membrane glomerulonephritis. Kidney Int. 2002;61:2078–2089
  21. Davis B, Dei Cas A, Long DA, et al. Podocyte-specific expression of angiopoietin-2 causes proteinuria and apoptosis of glomerular endothelia. J Am Soc Nephrol. 2007;18:2320–2329
  22. Post S, Peeters W, Busser E, et al. Balance between angiopoietin-1 and angiopoietin-2 is in favor of angiopoietin-2 in atherosclerotic plaques with high microvessel density. J Vasc Res. 2008;45:244–250
  23. Schwarz A, Mengel M, Gwinner W, et al. Protocol biopsy program after renal transplantation: Structure and first results. Transplant Proc. 2002;34:2238–2239
  24. Kumpers P, Koenecke C, Hecker H, et al. Angiopoietin-2 predicts disease-free survival after allogeneic stem cell transplantation in patients with high-risk myeloid malignancies. Blood. 2008;112:2139–2148
  25. Lukasz A, Hellpap J, Horn R, et al. Circulating angiopoietin-1 and angiopoietin-2 in critically ill patients: Development and clinical application of two new immunoassays. Crit Care. 2008;12:R94
  26. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277:55–60
  27. Weibel ER, Palade GE. New cytoplasmic components in arterial endothelia. J Cell Biol. 1964;23:101–112
  28. Fiedler U, Scharpfenecker M, Koidl S, et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood. 2004;103:4150–4156
  29. Pinsky DJ, Naka Y, Liao H, et al. Hypoxia-induced exocytosis of endothelial cell Weibel-Palade bodies (A mechanism for rapid neutrophil recruitment after cardiac preservation). J Clin Invest. 1996;97:493–500
  30. Reidy MA, Chopek M, Chao S, McDonald T, Schwartz SM. Injury induces increase of von Willebrand factor in rat endothelial cells. Am J Pathol. 1989;134:857–864
  31. Schmidt RJ, Baylis C. Total nitric oxide production is low in patients with chronic renal disease. Kidney Int. 2000;58:1261–1266
  32. Matsushita K, Morrell CN, Cambien B, et al. Nitric oxide regulates exocytosis by S-nitrosylation of N-ethylmaleimide-sensitive factor. Cell. 2003;115:139–150
  33. Yao D, Taguchi T, Matsumura T, et al. High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A. J Biol Chem. 2007;282:31038–31045
  34. Fiedler U, Reiss Y, Scharpfenecker M, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med. 2006;12:235–239
  35. Goettsch W, Gryczka C, Korff T, et al. Flow-dependent regulation of angiopoietin-2. J Cell Physiol. 2008;214:491–503
  36. Aicher A, Zeiher AM, Dimmeler S. Mobilizing endothelial progenitor cells. Hypertension. 2005;45:321–325
  37. Haller H, de Groot K, Bahlmann F, Elger M, Fliser D. Stem cells and progenitor cells in renal disease. Kidney Int. 2005;68:1932–1936
  38. Davis S, Papadopoulos N, Aldrich TH, et al. Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering. Nat Struct Biol. 2003;10:38–44
  39. Rondaij MG, Bierings R, Kragt A, van Mourik JA, Voorberg J. Dynamics and plasticity of Weibel-Palade bodies in endothelial cells. Arterioscler Thromb Vasc Biol. 2006;26:1002–1007
  40. Boulanger CM, Amabile N, Guerin AP, et al. In vivo shear stress determines circulating levels of endothelial microparticles in end-stage renal disease. Hypertension. 2007;49:902–908
  41. Tressel SL, Huang RP, Tomsen N, Jo H. Laminar shear inhibits tubule formation and migration of endothelial cells by an angiopoietin-2 dependent mechanism. Arterioscler Thromb Vasc Biol. 2007;27:2150–2156
  42. Kanazawa H, Nomura S, Asai K. Roles of angiopoietin-1 and angiopoietin-2 on airway microvascular permeability in asthmatic patients. Chest. 2007;131:1035–1041
  43. Oliner J, Min H, Leal J, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell. 2004;6:507–516
  44. Tressel SL, Kim H, Ni CW, et al. Angiopoietin-2 stimulates blood flow recovery after femoral artery occlusion by inducing inflammation and arteriogenesis. Arterioscler Thromb Vasc Biol. 2008;28:1989–1995

 Originally published online as doi:10.1053/j.ajkd.2008.11.030 on March 6, 2009.

 S.D. and P.K. contributed equally to this work.

PII: S0272-6386(09)00027-4

doi: 10.1053/j.ajkd.2008.11.030

American Journal of Kidney Diseases
Volume 53, Issue 5 , Pages 770-778 , May 2009

Article Tools

* Image Usage & Resolution